Australia's Dimerix rises on patent approval in Mexico
14/09/2026 04:59
BUZZ-Australia's Dimerix rises on patent approval in Mexico ** Shares of Australia's Dimerix DXB.AX rise as much as 10% to A$0.275, marking their biggest pct gain since August 20
** Clinical-stage biopharmaceutical company says Mexico has granted a patent for DMX-652, a drug candidate for acute kidney injury
** The patent expands protection for DMX-652 in Mexico, one of Latin America's largest pharmaceutical markets
** Co says the approval strengthens the commercial potential of DMX-652, following a similar approval for the drug in U.S.
** YTD down 53.6%, including the session's moves
(Reporting by Paridhi Minda in Bengaluru)
Recent news on Dimerix
See all newsBrief: Dimerix Says Mark Diamond To Retire As Chair
Australia's Dimerix gains as first patient completes four years on kidney disease drug
Brief: Dimerix Says Waiver Permits Security Grant To Skiptan Entities Without Shareholder Approval
Australia's Dimerix rises on patent approval in Mexico
Brief: Dimerix Secures A$34 Million Non-Dilutive Funding Facility